Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11279289 | 0.82 | PRCP (0.31) | — | |
| SCHEMBL9586346 | 0.82 | PRCP (0.31) | — | |
| SCHEMBL8692806 | 0.77 | — | — | |
| SCHEMBL7200857 | 0.75 | — | — | |
| SCHEMBL1292874 | 0.74 | SOS1 (0.31) | SOS1SOS2 | |
| SCHEMBL4241898 | 0.69 | SOS1 (0.39) | SOS1SOS2 | |
| SCHEMBL6024634 | 0.67 | SOS1 (0.31) | SOS1SOS2 | |
| SCHEMBL71979 | 0.65 | SOS1 (0.33) | SOS1SOS2 | |
| SCHEMBL9690498 | 0.64 | RAD52 (0.38) | SOS1SOS2 | |
| Hydrochloric Acid SCHEMBL31094814 | 0.63 | SOS1 (0.32) | SOS1SOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1784399-B1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2011-06-15 | — | — | EP | claimed |
| JP-4674236-B2 | — | — | 2011-04-20 | — | — | JP | claimed |
| US-7910585-B2 | Pyrimidine derivatives | NOVARTIS AG (CH) | 2011-03-22 | — | — | US | claimed |
| US-20080293708-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | claimed |
| JP-2008510765-A | — | — | 2008-04-10 | — | — | JP | claimed |
| EP-1784399-A2 | PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2007-05-16 | — | — | EP | claimed |
| WO-2006021457-A2 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2006-03-02 | — | — | WO | claimed |
| EP-1784399-B1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2011-06-15 | — | — | EP | disclosed |
| US-7910585-B2 | Pyrimidine derivatives | NOVARTIS AG (CH) | 2011-03-22 | — | — | US | disclosed |
| US-20080293708-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| EP-1784399-A2 | PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006021457-A2 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293708-A1 | Pyrimidine Derivatives | DPYD, TYMP, TYMS | SOS1 2835/4885SOS2 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.